Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2200+0.2000 (+4.98%)
At close: 04:00PM EDT
4.0100 -0.21 (-4.98%)
After hours: 04:29PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 430.66M
Enterprise value -93.58M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.85
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.68

Trading information

Stock price history

Beta (5Y monthly) 1.04
52-week change 3-55.11%
S&P500 52-week change 3-1.04%
52-week high 313.0000
52-week low 33.5500
50-day moving average 34.7926
200-day moving average 36.9299

Share statistics

Avg vol (3-month) 3516.1k
Avg vol (10-day) 3317.94k
Shares outstanding 5116.4M
Implied shares outstanding 6N/A
Float 835.14M
% held by insiders 164.67%
% held by institutions 134.43%
Shares short (12 May 2022) 42.29M
Short ratio (12 May 2022) 45.99
Short % of float (12 May 2022) 43.82%
Short % of shares outstanding (12 May 2022) 41.97%
Shares short (prior month 13 Apr 2022) 42.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Mar 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-17.63%
Return on equity (ttm)-29.96%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -137.61M
Net income avi to common (ttm)-137.72M
Diluted EPS (ttm)-1.3110
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)527M
Total cash per share (mrq)4.53
Total debt (mrq)2.76M
Total debt/equity (mrq)0.55
Current ratio (mrq)14.87
Book value per share (mrq)4.39

Cash flow statement

Operating cash flow (ttm)-95.65M
Levered free cash flow (ttm)-44.46M